A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.

Seventy-six cytomegalovirus (CMV)-seropositive lung transplant recipients receiving valganciclovir (900 mg/day) for CMV prophylaxis were compared with a group of 87 patients receiving oral ganciclovir (3000 mg/day). Prophylaxis was administered to day 120 post-transplantation and follow-up was 1 year. In addition, a study was conducted on risk factors for CMV infection/disease. CMV disease incidence was 7.9% and 16.1% for valganciclovir and oral ganciclovir, respectively (p = 0.11). Patients receiving valganciclovir had fewer viral syndromes (2.6% vs. 11.5%, p < 0.05), a similar rate of tissue-invasive disease (5.2% vs. 4.6%, p = ns), longer time-to-onset of CMV infection/disease (197.5 vs. 155.2 days, p < 0.05), and a lower probability of infection/disease while on prophylaxis (1.3% vs. 12.6%, p < 0.01). Nonetheless, leukopenia incidence was higher with valganciclovir (15.8% vs. 2.3%, p < 0.01), as was the need for treatment withdrawal due to adverse effects (11.8% vs. 1.1%, p < 0.01). CMV infection was similar in both groups (32.9% vs. 34.5%). Induction therapy with basiliximab and glucocorticosteroid treatment were independent risk factors for developing CMV infection/disease. In conclusion, valganciclovir prophylaxis results in a low incidence of CMV disease in lung transplant recipients and appears more effective than oral ganciclovir. Despite the comparatively higher incidence of adverse events with valganciclovir, the drug can be considered safe for prophylaxis.

Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome.

Bronchiolitis obliterans syndrome (BOS) continues to be the main factor limiting the long-term survival of lung transplant recipients. The objective of this study was to prospectively assess the impact of conversion from cyclosporine (CsA) to tacrolimus on lung function in patients who developed BOS while receiving CsA-based immunosuppressive therapy. A total of 79 patients with BOS were included in the study. Sixty percent of patients had stage II or III BOS according to the International Society for Heart and Lung Transplantation criteria. Mean time from transplantation was 30.4 +/- 21.9 months and all patients were on CsA therapy at enrollment in the study, with mean trough levels of 232.75 +/- 98.26 ng/mL. After conversion, tacrolimus trough levels were 11.0 +/- 3.6 ng/mL at 3 months and 9.0 +/- 3.4 ng/mL at 12 months. Sixteen deaths occurred during the first year postconversion, 56% of which were due to respiratory failure. Comparison of forced expiratory volume in 1 second (FEV(1)) preconversion versus postconversion showed a change in the slope of the FEV(1)-time curve. The slope of the preconversion curve was -0.44 versus a zero slope, whereas the slope of the postconversion curve was 0.005, with a statistically significant difference between both slopes. This change in slopes, which was also seen in FEV(1%), suggests that lung function loss closed after conversion from CsA to tacrolimus supporting this therapeutic strategy in lung transplant recipients with BOS treated with CsA.

Utility of home oximetry as a screening test for patients with moderate to severe symptoms of obstructive sleep apnea.

OBJECTIVE: To determine the value of home oximetry as a screening test in patients with moderate to severe symptoms of obstructive sleep apnea (OSA). DESIGN: Retrospective, observational study. SETTING: The Sleep Unit of a tertiary referral, university hospital. PATIENTS: 116 patients referred for evaluation of moderate to severe symptoms of OSA in which both home oximetry and polysomnography (PSG) were performed. INTERVENTIONS: NA. RESULTS: Three numerical oximetry indices were evaluated: average of desaturations > or =4% and average of resaturations > or =3% per hour of analysis time (DI4% and RI3%, respectively); and cumulative percentages of time spent at saturations below 90% (CT90%). A qualitative assessment was also performed. Oximetry indices were compared with apnea/hypopnea index (AHI) by simple linear regression and Bland-Altman analyses. Optimal cut-off points, in terms of sensitivity and specificity, for the oximetry indices were searched using ROC analysis, at an AHI threshold of > or =10. The correlation between AHI and the desaturation indices was r = 0.50 for CT90%, r = 0.60 for DI4%, and r = 0.58 for RI3%. No bias was found between PSG and oximetry indices in Bland-Altman plots. Neither the numerical indices nor the qualitative analysis achieved an adequate (>0.8) area under the ROC curve. A CT90% <0.79 excluded OSA with 84% sensitivity. A DI4% > or =31.4 or a RI3% > or =40.5 diagnosed OSA with 97% specificity. Using these values, 38% of the patients would have been correctly classified by oximetry alone, 10% would have been incorrectly classified, and 50% could not have been classified with certainty. Eleven (15%) OSA patients would have been missed by oximetry. CONCLUSIONS: Correlation between home oximetry and PSG was not high. Oximetry was more useful to confirm than to exclude OSA in our study. Qualitative assessment was not better than numerical analysis. The greatest value of oximetry in this setting seems to be as a tool to rapidly recognize and treat more severe OSA patients in waiting list for PSG.

Recommendations on the use of everolimus in lung transplantation.

The antiproliferative effect of everolimus provides a therapeutic option in the immunosuppression therapy of lung transplantation, by reducing both the risk of acute rejection and the process of progressive fibrosis that determines chronic graft rejection. However, few data on the use of everolimus in lung transplantation have been published to date, and the specific indications of the drug, along with the most adequate time for its introduction or dosing, have not been defined yet. The aim of this article is to propose recommendations for the use of everolimus in lung transplant recipients, including indications, dosing schedules and the use of concomitant immunosuppression. This consensus document has been developed by experts of all the Spanish lung transplant groups from the review of the existing literature and the clinical experience.